Overview

AZD7687 Multiple Ascending Dose Study

Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
0
Participant gender:
All
Summary
The aim of the study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD7687 following multiple ascending dose administrations in in overweight to obese but otherwise healthy male subjects
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
AstraZeneca
Criteria
Inclusion Criteria:

- Provision of signed and dated, written informed consent prior to any study specific
procedures

- suitable veins for cannulation or repeated venepuncture.

- Have a body mass index (BMI) between 27 and 35 kg/m2

Exclusion Criteria:

- Fasting serum (S)-glucose ≥7.0 mmol/L or non-fasting S-glucose ≥11.1 mmol/L at
screening.

- Any eating disorder or actively attempting to loose weight within 3 months prior to
enrolment.

- Smoking more than 7 cigarettes per week from time of consent